We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -3.51% | 1.375 | 1.35 | 1.40 | 1.425 | 1.375 | 1.425 | 958,802 | 09:31:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.26 | 10.62M |
From Apr 2019 to Apr 2024
TIDMSTX
RNS Number : 3693P
Shield Therapeutics PLC
31 August 2017
Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017
London, UK, 31 August 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive Officer, will present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017 at 9:05 AM ET in New York. Mr. Sterritt will give a corporate overview, review the Company's late-stage and commercial product portfolio, and provide an update on upcoming milestones, including key clinical trial readouts and potential subsequent regulatory submission.
An audio webcast of the presentation will be available in the events section of the Company's website, or by clicking here. A replay will be available for a limited time following the presentation.
About Shield Therapeutics
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals, which address areas of unmet medical need. The Group has a marketed product, Feraccru(R), for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.
For further information please contact:
Shield Therapeutics plc +44 (0) 207 186 8500
Joanne Estell, Chief Financial Officer
Karl Keegan, Corporate Development Director
Nominated Adviser and Joint Broker +44 (0)20 3100 2222
Liberum Capital Limited
Christopher Britton
Steve Pearce
Jonathan Wilkes-Green
Joint Broker +44 (0)20 7418 8900
Peel Hunt LLP
James Steel
Alastair Rae
Oliver Jackson
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
shieldtherapeutics@consilium-comms.com
U.S Investor Relations + 1 (212)-599-1265
Lazar Partners Ltd.
Matthew Ventimiglia
mventimiglia@lazarpartners.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDMGFRMGFGNZZ
(END) Dow Jones Newswires
August 31, 2017 02:01 ET (06:01 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
